Allecra Therapeutics' Exblifep Approved by FDA for Complicated Urinary Tract Infections
The FDA granted Allecra with a five-year marketing exclusivity extension for Exblifep (cefepime/enmetazobactam) through the Generating Antibiotic Incentives Now Act.
